Valion Bio, Inc. (VBIO) · Oct 8, 2026 · Share issuance
$50K financing — 50 Series B shares plus warrants for 1,539 common shares; $50,000 total
Valion Bio’s financing gives the clinical-stage biotech another $50,000, but the closing also resets conversion terms and can increase future share issuance.
Valion Bio is a clinical-stage immunotherapeutics company developing Entolimod for radiation injury and immune-function applications, while also building a contract development and manufacturing business through Velocity Bioworks. This is a small funding bridge, not a business milestone. The company is issuing 50 Series B preferred shares and warrants for 1,539 common shares at an initial $2.5520 exercise price, bringing in just $50,000. The cash helps fund operations, but its size is immaterial relative to the company’s broader financing needs. 〔0〕 (Section 1 — Closing)
| Transaction term | Amount / detail |
|---|---|
| Series B preferred shares issued | 50 (Section 1 — Closing) |
| Warrant shares | 1,539 common shares (Section 1 — Closing) |
| Initial warrant exercise price | $2.5520 per share (Section 1 — Closing) |
| Gross proceeds | $50,000 (Section 1 — Closing) |
The more consequential feature is the repricing and dilution mechanics. Before closing, Valion must disclose every price adjustment triggered across the Series B and Series C preferred securities, the senior secured convertible note, and related warrants, including any additional securities that become issuable. That means this transaction does not merely add $50,000; it can also alter the conversion and exercise economics of instruments already outstanding. 〔1〕 (Section 2(d) — Closing conditions)
The closing is conditional on continued Nasdaq compliance. The purchaser can proceed only if the common stock remains listed and the company is meeting Nasdaq’s listing and maintenance requirements. 〔2〕 (Section 2(e) — Closing conditions) This is a financing condition, not evidence that Valion has solved its funding or operating challenge.
Bottom line: The filing modestly extends liquidity, but the $50,000 is too small to change Valion Bio’s clinical or operating trajectory. The real takeaway is incremental capital accompanied by potentially more dilution and repricing across an already complex financing structure.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!